The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO

Can leptomeningeal enhancement be linked to multiple sclerosis?

(2015) F. Barkhof et al.   NEUROLOGY

Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?

(2015) B. Bielekova et al.   NEUROLOGY

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

(2013) Sharmilee Gnanapavan et al.   PLoS One

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

(2012) M Khalil et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Neurofilament ELISA validation

(2009) Axel Petzold et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal